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Abstract
Purpose: To determine the effect of intravenous iron supplementation on performance, fatigue and overall mood in runners
without clinical iron deficiency.
Methods: Fourteen distance runners with serum ferritin 30–100 mg?L21 were randomly assigned to receive three blinded
injections of intravenous ferric-carboxymaltose (2 ml, 100 mg, IRON) or normal saline (PLACEBO) over four weeks (weeks 0,
2, 4). Athletes performed a 3,000 m time trial and 106400 m monitored training session on consecutive days at week 0 and
again following each injection. Hemoglobin mass (Hbmass) was assessed via carbon monoxide rebreathing at weeks 0 and
6. Fatigue and mood were determined bi-weekly until week 6 via Total Fatigue Score (TFS) and Total Mood Disturbance
(TMD) using the Brief Fatigue Inventory and Brunel Mood Scale. Data were analyzed using magnitude-based inferences,
based on the unequal variances t-statistic and Cohen’s Effect sizes (ES).
Results: Serum ferritin increased in IRON only (Week 0: 62.8621.9, Week 4: 128.1646.6 mg?L21; p = 0.002) and remained
elevated two weeks after the final injection (127.0666.3 mg?L21, p = 0.01), without significant changes in Hbmass.
Supplementation had a moderate effect on TMD of IRON (ES -0.77) with scores at week 6 lower than PLACEBO (ES -1.58,
p = 0.02). Similarly, at week 6, TFS was significantly improved in IRON vs. PLACEBO (ES –1.54, p = 0.05). There were no
significant improvements in 3,000 m time in either group (Week 0 vs. Week 4; Iron: 625.6655.5 s vs. 625.4652.7 s;
PLACEBO: 624.8647.2 s vs. 639.1659.7 s); but IRON reduced their average time for the 106400 m training session at week 2
(Week 0: 78.066.6 s, Week 2: 77.266.3; ES–0.20, p = 0.004).
Conclusion: During 6 weeks of training, intravenous iron supplementation improved perceived fatigue and mood of trained
athletes with no clinical iron deficiency, without concurrent improvements in oxygen transport capacity or performance.
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Introduction
Iron is an essential nutrient for the optimal functioning of the
human body [1]. Integral for hemoglobin synthesis, iron also plays
an important role in many cellular processes; particularly, oxygen
transport and storage, generation of energy through oxidative
phosphorylation [1] and enzyme function affecting intracellular
metabolism [2]. In addition, iron assists immune function, DNA
synthesis, the functioning of neurotransmitters and the formation
of myelin, and is therefore critical for normal brain function and
cognitive development [3].
Iron status is influenced by both intake from dietary sources and
iron loss through sweat and urine [4], gastrointestinal bleeding,
menstruation and trauma. In athletes, exercise stress may
exacerbate iron loss due to foot-strike hemolysis associated with
running [5]. Iron deficiencies are common in athletic populations,
and frequently manifest through feelings of lethargy, a lack of
energy and lowered perceived ability to train and perform [4]. In
clinical terms, iron deficiency is often classified as serum ferritin
values below ,22 mg?L21, with iron deficiency anemia diagnosed
when iron stores are exhausted (serum ferritin ,15 mg?L21), and
consequently hemoglobin (Hb) levels fall below 12 g?L21 [6].
However, even amongst the medical literature there remains wide
debate as to the most appropriate thresholds for diagnosis and
when to begin supplementation, particularly in athletes [7].
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Iron supplementation, typically via the oral route, is commonly
used for the treatment of iron deficiency. Recently, carbohydrate-
encased intravenous (IV) compounds such as ferric carboxymal-
tose have proven successful in treating iron-deficiency anemia [8]
and improving fatigue [9] in an outpatient setting. Krayenbuehl et
al. [10] examined the effect of IV iron (III)-hydroxide sucrose on
fatigue in non-anemic, premenopausal women with serum ferritin
,50 mg?L21 using a placebo-controlled blinded design. Reduced
feelings of perceived fatigue were observed following treatment but
without concomitant changes in hemoglobin concentration ([Hb]),
leading the authors to speculate that the non-hematological
functions of iron, namely its involvement in the formation of key
enzymes involved in oxidative metabolism [11–13], were respon-
sible for the observed benefits of the iron treatment.
Indeed, the chosen delivery route (intravenous as opposed to
oral), and subsequent bioavailability of the supplemented iron may
also be a contributing factor to relatively novel findings of the
Krayenbuehl study [14]. Recently, Garvican et al. [15] compared
the efficacy of 6 weeks of oral versus IV iron supplementation in
distance runners with ‘‘low’’ (initial serum ferritin,35 mg.L21 and
transferrin saturation ,20%, or serum ferritin ,15 mg.L21) or
‘‘suboptimal’’ (serum ferritin ,65 mg.L21) iron status. Whilst both
forms of supplementation improved iron status, the increase in
serum ferritin was greater in the IV treated group and
improvements in hemoglobin mass (Hbmass), maximal aerobic
power (VO2max) and run time to exhaustion were evident only in
the IV treated athletes with initial ‘‘low’’ iron status. Increases in
Hbmass were not observed in the ‘‘suboptimal’’ group suggesting
that their iron stores did not limit erythropoiesis or aerobic
capacity. Unfortunately, neither subjective measures nor perfor-
mance per se were formally assessed by Garvican et al. [15], so
conclusions about any other potential benefits (non-hematological
or otherwise) of IV iron therapy for an athletic population could
not be drawn.
At present, the optimal iron status for overall wellbeing and
training ability (that is, over and above that which is required for
erythropoiesis) in athletic populations is unclear. Previous inves-
tigations of the benefit of oral supplementation for endurance
performance in athletes without a clinical iron deficiency, i.e.
‘‘normal’’ iron status, have been equivocal [4] and as a result,
routine supplementation for iron-replete individuals is not
encouraged. However the recent findings of Krayenbuehl et al.
(2011) suggest that IV iron supplementation may afford some
potential benefits unrelated to erythropoiesis or oxygen transport,
due to its high bioavailability [16] compared with oral supple-
ments [15], which may have consequences for athletic perfor-
mance and thus permit the topic to be revisited. Nonetheless, the
ethical and potential health implications (both long and short term)
of IV iron supplementation for athletes considered ‘‘clinically
normal’’ in terms of iron status should also be considered,
particularly in regard to risk of toxicity and iron overload, and
notwithstanding the difficulty in determining the appropriate IV
iron dose for such individuals.
Given the efficacy of the newer formulations of iron (as opposed
to oral supplementation) at improving fatigue in clinical settings
[14,17], the aim of the present study was to assess the impact of
intravenous iron supplementation on perceived fatigue, mood
disturbance, training ability and running performance in non-
anemic athletes with clinically normal serum ferritin levels.
Methods
Ethics Statement
The study was approved by both the Australian Institute of
Sport Human Ethics Committee and the University of Canberra
Human Research Ethics Committee. All athletes provided written
informed consent prior to participation.
Study design
Highly trained distance runners with clinically normal iron
status (serum ferritin 30–100 mg.L21) were randomly assigned to
receive either 2 ml (100 mg) of ferric carboxymaltose (IRON) or
normal saline (PLACEBO) intravenously every fortnight for four
weeks. Each IV injection was closely followed by a 3000 m time
trial run and a monitored training session consisting of an all-out
400 m time trial and 106400 m training session, performed on
consecutive evenings during the months of June and July in
Canberra, Australia, with mean environmental temperature of
10.4uC. Iron status, mood and fatigue were examined throughout,
with Hbmass assessed pre and post the intervention period
(Figure 1).
Inclusion/Exclusion criteria
Non-anemic athletes ([Hb]. 12 g.d?L21) with serum ferritin
between 30–100 mg?L21 (determined in duplicate prior to
inclusion in the study) were screened by a medical doctor to
determine their suitability for participation. Athletes excluded
from participation were those currently taking oral supplementa-
tion or presenting with iron deficiency anemia, anemia not related
to simple iron deficiency, serum ferritin ,30 mg.L21 or.
100 mg.L21, previously documented hypersensitivity to iron, iron
overload, acute illness, renal and endocrine disorders, pregnancy,
or those having completed altitude training within one month
prior.
Participants
Fourteen trained distance runners (six males, eight females) were
recruited from local distance running groups (Table 1). All athletes
had a minimum three-year consistent training history, and were
competitive at State level or above. All athletes were familiar with
the running tests employed, since similar training sessions were
performed regularly within their training groups.
Hemoglobin Mass
Hemoglobin mass was measured prior to the study, and two
weeks following the final injection (week 6) using the optimized
carbon monoxide (CO) rebreathing method of Schmidt and
Prommer [18], whereby a 1.2 ml?kg21 bolus of CO was
rebreathed through a closed-system spirometer for two minutes.
A CO-oximeter (OSM3, Radiometer, Copenhagen, Denmark)
measured the percent carboxyhemoglobin of capillary blood at 0
and 7 minutes post-rebreathing, with five replicates of each sample
performed where possible. Typical error, calculated previously
from duplicate measures on a separate group of distance runners
was 1.6 % (90% CL 1.3 to 2.2%) [15].
Familiarization
One to two weeks before the study commenced, two 3000 m
time trials and one 400 m time trial were performed within one
week on a synthetic 400 m running track for familiarization.
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Intervention
Participants were pair-matched by an independent researcher
based on their initial serum ferritin level, Hbmass, personal best
time for 3000 m and aerobic fitness (VO2max, assessed at the start
of the study as described previously [15]). Individuals were then
randomly assigned to either the IRON (n= 7) or PLACEBO
(n=7) group to receive three fortnightly injections over four weeks
(weeks 0, 2, 4). The IRON group received 2 ml (100 mg) of ferric
carboxymaltose solution (Ferinject, Vifor Pharma Ltd, Switzer-
land), whilst the corresponding PLACEBO group received 2 ml of
0.9% saline solution (Sodium chloride 0.9%).
Prior to each injection, and at least 12 h since the last training
session, a venous blood sample (5 ml) was obtained via venepunc-
ture by a trained phlebotomist to assess [Hb], hematocrit (Hct),
and iron status (serum ferritin, soluble iron, transferrin and percent
transferrin saturation (TSAT). Whole blood was analyzed within
four hours of collection (XT-2000i, Sysmex Corporation, Japan),
whilst iron status was assessed from serum (Integra 400 biochem-
istry analyzer, Roche Diagnostics, Switzerland). If Hct values
exceeded 50%, or serum ferritin values exceeded 200 mg?L21 for
females, or 300 mg?L21 for males, then iron supplementation
would not be performed and instead replaced by saline. Each
injection was performed by a medical practitioner via an
indwelling venous cannula in the forearm after first flushing with
2 ml of 0.9% saline. All participants were monitored for heart rate,
blood pressure, oxygen saturation and temperature by medical
staff prior to administration, and every five minutes for 15 minutes
afterwards in case of any adverse reactions. Throughout each
injection, the participant’s arm was shielded using a screen with
the injection solution prepared out of sight. In addition to all
athletes, all research staff associated with the testing and training
sessions were blinded to the treatment groups and were unable to
access blood results, nor preside over the injections. Thus, only the
medical staff administering the injections had access to grouping
allocation information.
Fatigue and Mood Questionnaires
Participants were assessed fortnightly for six weeks for their
perceptions of fatigue and mood disturbance using the Brief
Fatigue Inventory (BFI) [19] and Brunel Mood Scale (BRUMS)
[20,21] (Figure 1). The BFI consists of nine standardized questions
that participants answered on a scale of 1 ‘‘No fatigue’’ to 10 ‘‘As
bad as you can imagine’’, as previously detailed [10]. The resulting
scores from each question were averaged to produce a Total
Fatigue Score.
Mood was assessed using the Brunel Mood Scale (BRUMS)
[20,21], a 24-item questionnaire for assessment of mood descrip-
tors including Tension, Depression, Anger, Fatigue, Vigor and
Confusion. Each item was anchored by a 5-point Likert scale from
0 ‘‘Not at all’’ to 4 ‘‘Extremely’’ according to how participants feel
‘‘right now’’. Raw scores for each question and the related mood
descriptor were converted to standard T-scores using normative
data [22] to produce a final score, with Total Mood Disturbance
then calculated by adding each of the scores for the mood
descriptors and subtracting the score for Vigor [23].
Performance Testing Set: 3000 m Time Trial
The day following each injection (week 0, 2, and 4), and
approximately two weeks after the completion of the supplemen-
tation period (week 6 follow-up), participants completed a
maximal effort 3000 m time trial individually on a synthetic
outdoor 400 m (7.5 laps) running track (Figure 1) to assess their
maximal running performance capability. The 3000 m distance
was chosen since it is run at speeds associated with VO2max, and
has been shown previously to be a reliable indicator of running
performance in trained runners [24]. Athletes were familiar with
the protocol and were blinded to pace and time during the effort.
Total time was recorded via a manual stopwatch (S056-4000,
Seiko, Japan). BLa was measured one minute post-trial, as well as
RPE using the 6-20 Borg Scale [25].
Figure 1. Schematic outline of the study design and testing sessions. BRUMS: Brunel mood Scale; BFI: Brief fatigue Inventory. Weekly
injections performed on day 1, followed by 3000 m time trial on day 2 and monitored training session (400 m time trial/10 min recovery/106400 m)
on day 3.
doi:10.1371/journal.pone.0108042.g001
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Monitored Training Set: 106400 m
In order to assess the athletes’ ability to recover from the time
trial, and their subsequent readiness to train, a monitored training
session was completed 22–24 hours after the 3000 m time trial at
week 0, 2 and 4. The timeframe between the time trial and
monitored training session was 024 h shorter than typically
experienced by the athletes, but is reflective of competition
schedules at major championship meets where athletes may be
required to complete heats and finals on consecutive days. After a
standardized self-selected warm-up, participants completed an all-
out 400 m time trial individually. BLa and RPE were recorded
three minutes post-trial. After 10 minutes of active recovery,
athletes undertook as a group a training session consisting of
106400 m, on a two minute time cycle (Figure 1), with individual
lap times recorded via manual stopwatch. Mean lap time was
calculated as the average of the 10 lap times. BLa was measured
one minute after completion of the final 400 m lap. After 10 min,
session RPE was obtained using the 1–10 Borg Scale for Session
RPE (sRPE) [26].
Training and Lifestyle
Participants were asked to record their training daily using an
electronic training diary for the duration of the study period. In
addition to recording total distance and training time, they were
asked to rate their feelings related to ‘‘How ready do you feel to
train today? How easy was it to get out of bed this morning? How
energized do you feel today? How much did you give in your
training today? How sore are you feeling?’’ on a scale of 1–5.
Athletes were also instructed not to change their normal dietary
practices, and to refrain from taking any oral iron supplements.
Statistics
Potential differences between groups at baseline were assessed
using a Student’s t-test, with significance set to p#0.05. Otherwise,
magnitude-based inferences were used in order to define the
practical significance of the results using the unequal variances t-
statistic and Cohen’s Effect Sizes (ES) [27,28]. The differences and
associated 90% confidence limits (CL) for changes in hematolog-
ical, physiological and performance characteristics were examined
within each group over the duration of the study, as well as
between the groups for the differences in their respective changes
from baseline measures. Prior to analysis, raw data were log
transformed to reduce non-uniformity of errors. The magnitude of
an effect and the associated P-value was presented as percent
change and standardized mean differences (ES); calculated as the
difference in mean divided by the between-subject standard
deviation (SD); where a small effect is. 0.2, moderate. 0.6 and
large. 1.2 [27]. The reference threshold for the smallest
worthwhile change was set to 0.2, which is Cohen’s smallest
standardized effect calculated from the between-subject SD at
baseline. Effects were deemed unclear if the confidence interval
overlapped the thresholds for the smallest positive and negative
effects. Data are reported as mean 6 SD unless otherwise stated.
The overall change in the subjective parameters of the training
diaries was assessed with within-individual linear regressions
(change/day, with 90% CL) as described by others [29]. Trends
were deemed substantial if the 90% CL did not overlap zero.
Differences of the slopes between the IRON and PLACEBO
groups were also assessed using magnitude based inferences as
described above [27].
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Results
Study Population
There were no significant differences between the IRON and
PLACEBO groups at the start of the study in terms of baseline
characteristics (Table 1), hematological parameters (Table 2), or
mood scores associated with the BRUMS (Figure 2A). However at
baseline, IRON had a significantly higher Total Fatigue Score
than PLACEBO on the BFI (Figure 2B, p = 0.04).
Supplementation, Hematology and Iron profile
Each scheduled injection was administered without incident.
Serum ferritin values did not change significantly in PLACEBO
but increased two-fold from baseline in the IRON group at week 4
(Week 0: 62.8621.9, Week 4: 128.1646.6 mg?L21; p = 0.002) and
remained elevated two weeks after the final injection (127.06
66.3 mg?L21; p = 0.01; Table 2). There were no statistically
Figure 2. Changes in mood and fatigue scores during the
study. A) Total Mood Disturbance from the Brunel Mood Scale and B)
Total Fatigue Score from the Brief Fatigue Inventory. Data are presented
in raw form on the Left Y-axis and as percent change from week 0 on
the Right Y-axis (mean 6 SD). Within a group change from Week 0:
{ small effect (Effect size. 0.2), {{ moderate effect (Effect size.0.6);
between group percent change from week 0 at matched time; * p#
0.05; { small effect (Effect size. 0.2), {{ moderate effect (Effect size.
0.6), {{{ Large effect (Effect size. 1.2); V denotes difference between
groups at week 0.
doi:10.1371/journal.pone.0108042.g002
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significant changes in Hbmass, [Hb] or Hct in either group over
the course of the investigation (Table 2).
Fatigue Scores
Brunel Mood Scale. Iron supplementation had a moderate
(but not significant) effect on Total Mood Disturbance (Figure 2A),
with values within the IRON group tending to be lower than
baseline at week 2 (ES –0.64, p= 0.06) and 6 (ES –0.77, p = 0.08).
Between the groups, Total Mood Disturbance significantly
improved in IRON compared with PLACEBO (Figure 2A), at
both week 2 (% change compared with PLACEBO; 90% CL, ES,
p value: 212.3%; 219.8 to 24.1%, 20.95, p = 0.02) and week 6
(219.6%; 230.4 to 27.1%, 21.58, p = 0.02).
Brief Fatigue Inventory. Within the IRON group, supple-
mentation resulted in a trend to decrease the Total Fatigue Score
at week 6 (ES -1.35, p = 0.09), but the latter large effect size failed
to attain statistical significance (Figure 2B). Between the groups,
Total Fatigue Score in the IRON group significantly improved at
week 6 compared to PLACEBO (263.0%; 283.7 to 216.1%,
21.54, p = 0.05).
Running performance
3000 m Time Trial. Mean 3000 m run time did not change
significantly within IRON during the study but PLACEBO were
slower than week 0 at week 4 (p = 0.04). Therefore, at week 4 there
was a small effect on 3000 m time between the groups, with IRON
faster than PLACEBO (22.1 %; 23.8 to 0.3 %, 0.22; p = 0.05);
Table 3). Compared with PLACEBO, the BLa of IRON was
reduced at week 2 (229.5%; 243.7 to 211.7%, 21.00, p = 0.02),
week 4 (230.8%; 244.0 to 214.5%, 21.06, p= 0.01) and week 6
(235.8%; 248.4 to 220.1%, 21.27, p = 0.003; Figure 3A).
Between the groups, iron supplementation had no significant
effect on RPE.
All-out 400 m Time Trial. All-out 400 m time did not
change significantly within or between either group over the
course of the study (Table 3). Differences between the groups for
changes in BLa and RPE were not significant (Figure 3B).
106400 m Training Session. The average time for the
106400 m session of the IRON group was faster at week 2
(20.8%; 21.2 to 20.5%, 20.09, p = 0.004) compared with week
0. There were no significant differences within PLACEBO over
time (Table 3), nor were there any significant differences between
groups. Between the groups, iron supplementation had no
significant effect on RPE or BLa (Figure 3C).
Training Diaries
Day-to-day mean training diary scores improved in the
following areas within the IRON group only: ‘‘How easy was it
to get out of bed this morning?’’, ‘‘How ready do you feel to train
today?’’, and ‘‘How energized do you feel today?’’ (Figure 4). The
observed positive effects for these questions were greater in IRON
compared with PLACEBO (Effect size; 90CL: ‘‘How easy was it to
get out of bed this morning?’’0.88; 0.04 to 1.71; ‘‘How ready do
you feel to train today?’’1.12; 0.38 to 1.86, and ‘‘How energized
do you feel today?’’ 1.04; 0.11 to 1.97).
Discussion
The main finding of the present study was that, compared with
PLACEBO, three fortnightly IV injections of ferric carboxymal-
tose over 4 weeks improved self-reported perceptions of fatigue
and reduced mood disturbance in trained distance runners with
‘‘clinically normal’’serum ferritin levels between 30 and
100 mg?L21, without concomitant changes in Hbmass or [Hb].
Supplementation had no acute effects on 3000 m running
performance; however iron supplemented athletes decreased their
106400 m training set time at week 2, and recorded improve-
ments in their perceptions about their preparedness to train, which
collectively may indicate a potential training benefit of IV iron for
the treatment group.
The most widely accepted clinical threshold for iron deficiency
is 22 mg?L21 [30], where storage iron is exhausted but transport
and functional compounds are maintained. When ferritin stores
fall below 22 mg?L21, functional compounds become compro-
mised, including but not limited to hemoglobin, myoglobin and
cytochromes [30]. However, the ‘‘optimal’’ level for serum ferritin
is still unknown in terms of athletic performance and an athlete’s
ability to train and recover between sessions over weeks or months.
Uncertainty is due largely to discrepancies in the literature
regarding the effect of iron supplementation, particularly in
athletes with ‘normal’ iron status [2], and hampered by a wide
variety of supplementation methods and protocols [7]. In the
present study, we specifically recruited subjects with clinically
normal ferritin levels (30–100 mg?L21), whose Hbmass was
therefore unlikely to be compromised [15], in order to investigate
possible non-hematological effects of IV iron supplementation;
that is, those unrelated to erythropoiesis or oxygen transport, such
as subjective wellbeing and training ability.
Intravenous ferric carboxymaltose supplementation increased
serum ferritin throughout the supplementation period. Further,
serum ferritin remained elevated by approximately double the pre-
treatment levels two weeks following the final injection. However,
Hbmass and [Hb] did not change, confirming previous research
[15] but also indicating that the observed reductions in fatigue and
mood disturbance in the iron treatment group, compared to
placebo, were unlikely to be related to oxygen-carrying capacity.
When storage iron is. 35 mg?L21, erythropoiesis and thereby
oxygen transport, are unlikely to be affected [15]. However, it is
possible that if the amount of iron available for the formation of
enzymes and compounds associated with muscle metabolism is
insufficient, then endurance performance may also become
impaired [31]. Since it would appear that the supplemental iron
provided in the present study was not required for the formation of
Hb, it is possible that the available iron may have been shuttled
towards oxidative enzymes for intracellular metabolism and
electron transport [1]. However, in the present study, 3000 m
running time was not acutely improved following each injection;
indicating neither a direct performance advantage following IV
iron administration nor a placebo effect of an injection. Further,
although subtle improvements in the 106400 m training set were
observed in the IRON group at week 2, overall our results do not
provide compelling evidence for any performance advantage
arising from increasing ferritin stores. Of note, however, is the
observation that 3000 m performance was worse in the PLACE-
BO group at week 4, and as a result the IRON group performed
significantly better. These findings provide tentative evidence that
the IRON group performed more consistently throughout the
study, and may be related to improved perceptions of fatigue and
well-being as opposed to effects at a metabolic level.
The presence of blood lactate, a gross indirect measure of
anaerobic metabolism, reflects the contribution of each of the
body’s energy systems with which an exercise effort is undertaken.
A decrease in BLa within the IRON group was observed following
the week 2 and week 6, 3000 m time trials, which is similar to
previous findings [32–34], whilst PLACEBO recorded higher BLa
for comparable run times. Hinton et al. [35] report that as a result
of iron deficits, the oxidative capacity of the muscle is reduced and
therefore the workload at which the ventilatory threshold and
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blood lactate accumulation occurs is lower [35]. Some studies have
reported no change in BLa following supplementation [36,37], but
discrepancies in time course of treatment and the chosen modality
(most have involved oral supplementation), dosage and study
design may have influenced these results. The iron recipients in the
present study may thus have improved aspects of their lactate
metabolism [1,34] as a result of treatment effects at a metabolic
level, although further investigation is required to confirm this
notion.
Iron deficiency without anemia can result in a greater energy
expenditure during a simulated time trial [38] as well as lower
exercise tolerance and a more prolonged recovery from exercise
[39]. The IRON group decreased their average 106400 m time
shortly after the second injection, even though their 3000 m and
all-out 400 m times did not improve. These results partially
support the notion of resilience to an exercise bout and weakly
suggest the iron supplemented group may have displayed a greater
ability to complete consecutive training sessions whilst carrying
potential fatigue from a prior effort. It is possible that improved
iron stores may result in greater coping ability and enhanced
recovery before the next session, which may in turn facilitate
augmented wellbeing and ability to train more effectively,
although further research is required.
There is evidence that iron insufficiencies impact mental
function and emotional health as a result of reduced neurotrans-
mitter activity in the brain and central nervous system [1]. Iron
therapy can result in improved cognitive function [40] and has
been associated with improvements in memory, energy and mood
[41], as well as improvement in subjective feelings of physical
fitness and performance [42,43]. This is supported by data in the
present study where the recipients of IV iron reported improve-
ment in total fatigue and total mood disturbance, in addition to an
improvement in their training diary scores relating to readiness to
train, energy levels and ease of getting out of bed. By contrast,
some studies have reported that iron supplementation has no
significant effect on deficiency symptoms, mood state [44] or
quality of life [45]. The discrepancy may be due to the oral
treatment modality examined by earlier researchers, which may
not deliver enough bioavailable iron for substantial cognitive
improvements.
Limitations
Despite careful pair matching of subjects based on initial
ferritin, Hbmass and performance characteristics, the PLACEBO
group reported lower fatigue scores on the one of the two
questionnaire scales (BFI) at the start of the study. The BFI is a tool
typically used to assess cancer-related fatigue but has been used
previously in a non-athletic population to assess iron related
fatigue [14]; whereas the BRUMS was developed for assessment of
mood (including fatigue) in performance environments. The
difference in baseline scores using the BFI highlights that the
presence of fatigue symptoms is not solely related to initial ferritin
level. Nonetheless, when the difference in change scores of both
scales (BRUMS and BFI) was analyzed, a superiority of the IRON
group over the PLACEBO group was observed, indicating a
possible role of supplemental iron in the reduction of perceived
fatigue and an improvement in overall mood. It should also be
noted that whilst improvements were observed in the self-reported
training diary scores of the IRON group, this method of reporting
is only typically used in an applied sport model as opposed to a
clinical setting.
No clear acute or chronic benefits of iron supplementation on
3000 m running performance were observed although consistently
similar performances were evident throughout which was not the
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case in the PLACEBO group. Measuring a true maximal effort of
an individual as well as obtaining optimal performance on a
particular day, remain inherently difficult [46]. The very nature of
simulated performance testing means that is nearly impossible to
mimic real-life competition through a time trial or simulated
laboratory test, which may explain some early research reporting
no improvement in performance post-supplementation even in
iron-deficient participants [36,37,47]. A further limitation to
consider is that our total monitoring period was possibly too
short, particularly since we did not follow the 106400 m training
set at two weeks post injection.
Implications
This study demonstrated improvements in fatigue and mood
disturbance in the IRON group during a 6 week training period.
Whether or not such improvements in fatigue and mood
(potentially arising from elevated ferritin levels) may lead to better
training quality and subsequently improved performance over a
Figure 3. Blood lactate concentration (Bla) and Rating of Perceived Exertion (RPE) from the run trials over the course of the study.
A) 3000 m time trial; B) All-out 400 m time trial; C) 106400 m session. Data are presented in raw form on the Left Y-axis and as % change from week
0 on the Right Y-axis (mean 6 SD). Within a group change from Week 0: * p#0.05; { small effect (Effect size. 0.2), {{ moderate effect (Effect size.
0.6); between group percent change from PRE at matched time; { small effect (Effect size. 0.2), {{ moderate effect (Effect size. 0.6).
doi:10.1371/journal.pone.0108042.g003
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longer period of time cannot be determined from this study.
However, the long term or repeated use of iron supplementation in
athletes who are not iron deficient should not be advocated. In the
short-term, the efficacy of IV Iron supplementation for athletes
with moderate ferritin levels also requires careful consideration,
because a performance improvement remains unclear. For this
reason the data in this study do not provide strong evidence for IV
iron supplementation in athletes with clinically normal ferritin
levels, especially when taking into account the ethical and potential
health implications of sustained iron supplementation for iron
replete individuals. Specifically, the potential risk of toxicity and
iron overload following IV administration must be acknowledged,
particularly since the primary route for regulating whole body iron
stores is bypassed using this method, allowing ferritin levels to be
elevated rapidly. Therefore, IV injections should not be admin-
istered without first assessing existing iron stores, and careful
consideration of the total dose to be given, and its likely impact on
whole body iron stores, is required. IV iron should only be
administered under medical supervision, with patients closely
monitored for adverse reactions. Follow-up tests should also be
conducted to ensure ferritin levels do not exceed healthy limits.
Lastly, researchers need to be acutely up to date with any changes
to the World Anti-Doping Agency code when planning future
research with elite athletes [48].
Conclusion
Four weeks of IV ferric carboxymaltose supplementation
doubled serum ferritin, and decreased feelings of fatigue and
mood disturbance in non-anemic athletes with initial ferritin levels
in the clinically normal range of 30–100 mg?L21 without
associated changes in Hbmass. Running performance was not
acutely affected by iron supplementation, but there was some
evidence from self-reported training diaries that participants felt
more able to train. Together, these results indicate a potential
psychobiological influence of iron supplementation on feelings of
mood and fatigue in athletic populations with clinically normal
serum ferritin.
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